Evaluation of Gingival Hyperplasia Caused by Medications

Authors: Ilma Robo, Saimir Heta, Greta Plaka, Vera Ostreni

Abstract:

Purpose: Drug gingival hyperplasia is an uncommon pathology encountered during routine work in dental units. The purpose of this paper is to present the clinical appearance of gingival hyperplasia caused by medications. There are already three classes of medications that cause hyperplasia and based on data from the literature, the clinical cases encountered and included in this study have been compared. Materials and Methods: The study was conducted in a total of 311 patients, out of which 182 patients were included in our study, meeting the inclusion criteria. After each patient's history was recorded and it was found that patients were in their knowledge of chronic illness, undergoing treatment of gingivitis hypertrophic drugs was performed with a clinical examination of oral cavity and assessment by vertical and horizontal evaluation according to the periodontal indexes. Results: Of the data collected during the study, it was observed that 97% of patients with gingival hyperplasia are treated with nifedipine. 84% of patients treated with selected medicines and gingival hyperplasia in the oral cavity has been exposed at time period for more than 1 year and 1 month. According to the GOI, in the first rank of this index are about 21% of patients, in the second rank are 52%, in the third rank are 24% and in the fourth grade are 3%. According to the horizontal growth index of gingival hyperplasia, grade 1 included about 61% of patients and grade 2 included about 39% of patients with gingival hyperplasia. Bacterial index divides patients by degrees: grading 0 - 8.2%, grading 1 - 32.4%, grading 2 - 14% and grading 3 - 45.1%. Conclusions: The highest percentage of gingival hyperplasia caused by drugs is due to dosing of nifedipine for a duration of dosing and application for systemic healing for more than 1 year.

Keywords: Drug gingival hyperplasia, horizontal growth index, vertical growth index.

References:

[1] Carranza – Clinical Periodontology; Mosby 2009; Kapitulli Hiperplazia Gingivale.
[2] http://file.scirp.org/Html/htmlimages/1-1460252x/87838b1e-e34e-41df-8759-f6b26ab6b9e6.png.
[3] Seymour RA, Smith DG, Turnbull DN.; “The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients.”; J Clin Periodontol. 1985 Jul;12(6):413-9.
[4] Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy. Oral Surg Oral Med Oral Pathol. 1984;57:620–2. (PubMed).
[5] Margiotta V, Pizzo I, Pizzo G, Barbaro A. Cyclosporine and nifedipine induced gingival overgrowth in renal transplant patients: Correlations with periodontal and pharmacological parameters, and HLA-antigens. J Oral Pathol Med. 1996;25:128–34. (PubMed).
[6] Rees TD, Levine RA. Systemic drugs as a risk factor for periodontal disease initiation and progression. Compend Contin Educ Dent. 1995;16:20–42. (PubMed).
[7] Paramel Mohan Sunil, Jai Sanghar Nalluswami, Suman Jai Sanghar, and Issac Joseph; “Nifedipine-induced gingival enlargement: Correlation with dose and oral hygiene”; Curr Med Res Opin. 1988;10(10):652-5.
[8] Saito K, Mori S, Iwakura M, Sakamoto S. Immunohistochemical localization of transforming growth factor beta, b-FGF and HsgG in gingival hyperplasia induced by Nifedipine and phenytoin. J Periodontal Res. 1996;31:545–55. (PubMed).
[9] J Pharm Bioallied Sci. 2012 Aug; 4(Suppl 2): S191–S193.; doi: 10.4103/0975-7406.100268; PMCID: PMC3467881; PMID: 23066250.
[10] Grant RH, Parsonage MJ, Barot MH; “Phenytoin-induced gum hypertrophy in patients with epilepsy”; ISRN Dentistry Volume 2011 (2011).
[11] Luker J, Scully C, Oakhill A. Gingival swelling as a manifestation of aplastic anemia. Oral Surg Oral Med Oral Pathol. 1991;71:55–6. (PubMed).
[12] Milanes CL, Arminio A, Barrios Y, Garcia-Ramirez R, Herrera J, Leon I, et al. Safety in the switching traditional cyclosporin to microemulsion cyclosporin in stable renal transplant patients: Cooperative study. Invest Clin. 1995;36:183–96. (PubMed).
[13] Mavrogiannis M, Ellis JS, Seymour RA, Thomason JM. The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth. J Clin Periodontol. 2006;33:677–82. (PubMed).
[14] Haruna Hatahira, Junko Abe, Yuuki Hane, Toshinobu Matsui, Sayaka Sasaoka, Yumi Motooka, Shiori Hasegawa, Akiho Fukuda, Misa Naganuma, Tomofumi Ohmori, Yasutomi Kinosada, Mitsuhiro Nakamura; “Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases”; Pharm Health Care Sci. 2017; 3: 19. Published online 2017 Jul 19; doi: 10.1186/s40780-017-0088-5; PMCID: PMC5518137; PMID: 28729910.
[15] Ajay Chouksey, Nitin Awasthi, Jayesh Rai, Abhishek Chaudhary; “Association of drug-induced gingival enlargement (calcium channel blockers) and local factors: Who is the culprit?”; International Dental & Medical Journal of Advanced Research (2017), 3, 1–4.